Eosinophilic gastritis
disease diseaseOn this page
Summary
Eosinophilic gastritis (MONDO:0002840) is a disease and 14 clinical trials. Top therapeutic interventions include benralizumab, dupilumab, and lirentelimab. A subtype of gastritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 14
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | eosinophilic gastritis |
| Mondo ID | MONDO:0002840 |
| DOID | DOID:4030 |
| ICD-11 | 1944772274 |
| NCIT | C27052 |
| SNOMED CT | 66329006 |
| UMLS | C0267154 |
| MedGen | 120598 |
| GARD | 0023264 |
| Is cancer (heuristic) | no |
Also known as: eosinophilic gastritis
Disease family
This is a subtype of gastritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › stomach disorder › gastritis › eosinophilic gastritis
Related subtypes (15): gastroduodenal Crohn disease, viral gastritis, bacterial gastritis, fungal gastritis, lymphocytic gastritis, necrotizing gastritis, granulomatous gastritis, gastroduodenitis, alcoholic gastritis, chronic gastritis, gastric mucosal hypertrophy, chronic erosive gastritis, autoimmune gastritis, collagenous gastritis, pediatric collagenous gastritis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 14.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03473977 | PHASE2/PHASE3 | COMPLETED | Benralizumab for Eosinophilic Gastritis (BEGS) |
| NCT04322604 | PHASE3 | COMPLETED | A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
| NCT04620811 | PHASE3 | COMPLETED | An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
| NCT05152563 | PHASE3 | WITHDRAWN | A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis |
| NCT05251909 | PHASE3 | TERMINATED | Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) |
| NCT05831176 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have |
| NCT03496571 | PHASE2 | COMPLETED | A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis |
| NCT03664960 | PHASE2 | COMPLETED | An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis |
| NCT03678545 | PHASE2 | COMPLETED | Dupilumab in Eosinophilic Gastritis |
| NCT02523118 | Not specified | RECRUITING | OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages |
| NCT05219903 | Not specified | RECRUITING | National, Multicenter, Retrospective, Prospective Study to Evaluate Pediatric Gastrointestinal Eosinophilic Disorders |
| NCT05229432 | Not specified | RECRUITING | Study of Gastric Motility in Eosinophilic Gastritis |
| NCT01779154 | Not specified | WITHDRAWN | Eosinophilic Gastrointestinal Disorders Patient Registry |
| NCT02897271 | Not specified | COMPLETED | Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BENRALIZUMAB | 4 | 2 |
| DUPILUMAB | 4 | 2 |
| LIRENTELIMAB | 3 | 5 |
Related Atlas pages
- Drugs: Benralizumab, Dupilumab, Lirentelimab